| Symbol | BMKDF |
|---|---|
| Name | BIOMARK DIAGNOSTICS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | V6X 2W2 Canada BC 130 - 3851 Shell Rd |
| Telephone | +1 6043700779 |
| Fax | — |
| — | |
| Website | http://www.biomarkdiagnostics.com |
| Incorporation | CA |
| Incorporated On | 2014 |
| Employees | — |
| Fiscal Year | 3/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Manning Elliott LLP;MNP LLP; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Canadian Securities Exchange |
| CIK | — |
| Description | BioMark is a Canadian based company that is developing its advanced stage cancer diagnostic business. BioMarks cancer diagnostics technology platform leverages "Omics" and machine learning which allows for early cancer detection. BioMark is currently focused on bringing its cancer diagnostic and detection solution starting with its lung cancer assay to commercialization standards. It intends to commence distribution after securing its lab certification and regulatory acceptance is obtained. For more information please visit the companys website at www.biomarkdiagnostics.com Additional info from OTC: |
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
Read moreBioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
Read moreBioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
Read moreBioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Read moreBioMark Aligns with National Strategy to Slash Lung Cancer Mortality with Next-Gen Liquid Biopsy
Read moreBioMark’s Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
Read more